Treatment of early stage rheumatoid arthritis should continue to include conventional synthetic disease modifying drugs (DMARDs) plus steroids, advises the European League against Rheumatism (EULAR) in its latest recommendations on managing the disease, published in the Annals of the Rheumatic Diseases.

Read more...